Gemphire Therapeutics Stock Price, News & Analysis (NASDAQ:GEMP)

$6.66 -0.13 (-1.91 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$6.66
Today's Range$6.45 - $6.86
52-Week Range$6.07 - $21.59
Volume198,414 shs
Average Volume204,429 shs
Market Capitalization$93.54 million
P/E Ratio-1.97
Dividend YieldN/A
Beta3.9

About Gemphire Therapeutics (NASDAQ:GEMP)

Gemphire Therapeutics logoGemphire Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy. Gemcabene is liver-directed and inhibits apolipoprotein C-III (apoC-III) protein in the liver and may inhibit acetyl-CoA carboxylase (ACC) in the liver. Gemcabene blocks the overall production of hepatic triglycerides and cholesterol. Gemcabene has been tested as monotherapy and in combination with statins and other drugs in over 895 subjects, across approximately 18 Phase I and Phase II clinical trials. Gemcabene is used as an adjunctive therapy to reduce LDL-C, high-sensitivity C-reactive protein (hsCRP) and triglycerides.

Receive GEMP News and Ratings via Email

Sign-up to receive the latest news and ratings for GEMP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GEMP
CUSIPN/A
Phone734-245-1700

Debt

Debt-to-Equity Ratio1.00%
Current Ratio4.17%
Quick Ratio4.17%

Price-To-Earnings

Trailing P/E Ratio-1.97041420118343
Forward P/E Ratio-2.01
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.23 per share
Price / Book2.99

Profitability

Trailing EPS($3.38)
Net Income$-14,580,000.00
Net MarginsN/A
Return on Equity-170.04%
Return on Assets-120.55%

Miscellaneous

Employees114
Outstanding Shares13,780,000

Gemphire Therapeutics (NASDAQ:GEMP) Frequently Asked Questions

What is Gemphire Therapeutics' stock symbol?

Gemphire Therapeutics trades on the NASDAQ under the ticker symbol "GEMP."

How were Gemphire Therapeutics' earnings last quarter?

Gemphire Therapeutics Inc (NASDAQ:GEMP) issued its earnings results on Monday, November, 13th. The company reported ($0.82) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.68) by $0.14. View Gemphire Therapeutics' Earnings History.

When will Gemphire Therapeutics make its next earnings announcement?

Gemphire Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 21st 2018. View Earnings Estimates for Gemphire Therapeutics.

Where is Gemphire Therapeutics' stock going? Where will Gemphire Therapeutics' stock price be in 2018?

5 brokers have issued 1-year price targets for Gemphire Therapeutics' shares. Their forecasts range from $18.00 to $31.00. On average, they anticipate Gemphire Therapeutics' stock price to reach $25.80 in the next twelve months. View Analyst Ratings for Gemphire Therapeutics.

What are Wall Street analysts saying about Gemphire Therapeutics stock?

Here are some recent quotes from research analysts about Gemphire Therapeutics stock:

  • 1. According to Zacks Investment Research, "Gemphire Therapeutics Inc. is a biopharmaceutical company. It focused on developing and commercializing therapies for the treatment of dyslipidemia. The company's product candidate is gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies. Gemphire Therapeutics Inc. is headquartered in Northville, Michigan. " (2/15/2018)
  • 2. Canaccord Genuity analysts commented, "We believe gemcabene’s 40% hsCRP reduction is very meaningful, especially given that Novartis canikinumab reduced hsCRP and lowered Major Adverse Cardiac Events (MACE). In our view, gemcabene has lowering effects on important biomarkers beyond LDL, including triglycerides and hsCRP, differentiating the drug from competitors. Continue to anticipate positive INDIGO-1 data in 2018 We expect gemcabene to show a statistically significant reduction in triglycerides in the INDIGO-1 study in 2018, providing a major catalyst for shares to move higher. Importantly, many drugs can lower LDL cholesterol, but some have no effect on triglycerides, such as PCSK9 therapies." (10/13/2017)

Who are some of Gemphire Therapeutics' key competitors?

Who are Gemphire Therapeutics' key executives?

Gemphire Therapeutics' management team includes the folowing people:

  • Charles L. Bisgaier Ph.D., Chairman of the Board, Chief Scientific Officer (Age 63)
  • Steven R. Gullans Ph.D., Interim President, Interim Chief Executive Officer, Director (Age 64)
  • Mina Patel Sooch, President, Chief Executive Officer, Director (Age 49)
  • Jeffrey S. Mathiesen, Chief Financial Officer (Age 56)
  • Lee Golden, Chief Medical Officer (Age 49)
  • Seth Reno, Chief Commercial Officer (Age 50)
  • P. Kent Hawryluk, Independent Director (Age 48)
  • Kenneth W. Kousky, Independent Director (Age 62)
  • Pedro Lichtinger, Independent Director (Age 62)
  • Andrew Heroux Sassine, Independent Director (Age 52)

When did Gemphire Therapeutics IPO?

(GEMP) raised $30 million in an IPO on Friday, August 5th 2016. The company issued 3,000,000 shares at a price of $10.00 per share. Jefferies and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity and Roth Capital Partners were co-managers.

Who owns Gemphire Therapeutics stock?

Gemphire Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Northpointe Capital LLC (4.99%), Bamco Inc. NY (2.79%), Exchange Capital Management Inc. (0.40%) and Virtu Financial LLC (0.14%). Company insiders that own Gemphire Therapeutics stock include Andy Sassine, David Lowenschuss, Jeffrey S Mathiesen, Mina Sooch and Steven R PhD Gullans. View Institutional Ownership Trends for Gemphire Therapeutics.

Who sold Gemphire Therapeutics stock? Who is selling Gemphire Therapeutics stock?

Gemphire Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Exchange Capital Management Inc.. View Insider Buying and Selling for Gemphire Therapeutics.

Who bought Gemphire Therapeutics stock? Who is buying Gemphire Therapeutics stock?

Gemphire Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Bamco Inc. NY, Virtu Financial LLC and Northpointe Capital LLC. Company insiders that have bought Gemphire Therapeutics stock in the last two years include Andy Sassine, David Lowenschuss, Jeffrey S Mathiesen, Mina Sooch and Steven R PhD Gullans. View Insider Buying and Selling for Gemphire Therapeutics.

How do I buy Gemphire Therapeutics stock?

Shares of Gemphire Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Gemphire Therapeutics' stock price today?

One share of Gemphire Therapeutics stock can currently be purchased for approximately $6.66.

How big of a company is Gemphire Therapeutics?

Gemphire Therapeutics has a market capitalization of $93.54 million. The company earns $-14,580,000.00 in net income (profit) each year or ($3.38) on an earnings per share basis. Gemphire Therapeutics employs 114 workers across the globe.

How can I contact Gemphire Therapeutics?

Gemphire Therapeutics' mailing address is 17199 N. LAUREL PARK DRIVE SUITE 401, LIVONIA MI, 48152. The company can be reached via phone at 734-245-1700.


MarketBeat Community Rating for Gemphire Therapeutics (GEMP)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  144 (Vote Outperform)
Underperform Votes:  110 (Vote Underperform)
Total Votes:  254
MarketBeat's community ratings are surveys of what our community members think about Gemphire Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Gemphire Therapeutics (NASDAQ:GEMP) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $25.80$24.60$24.60$24.80
Price Target Upside: 164.89% upside202.58% upside174.55% upside178.65% upside

Gemphire Therapeutics (NASDAQ:GEMP) Consensus Price Target History

Price Target History for Gemphire Therapeutics (NASDAQ:GEMP)

Gemphire Therapeutics (NASDAQ:GEMP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/1/2018HC WainwrightReiterated RatingBuy$28.00LowView Rating Details
12/22/2017Roth CapitalReiterated RatingBuy$30.00MediumView Rating Details
10/27/2017Piper Jaffray CompaniesReiterated RatingOverweight -> Overweight$22.00N/AView Rating Details
10/23/2017Canaccord GenuityReiterated RatingBuy$31.00N/AView Rating Details
8/8/2017Jefferies GroupLower Price TargetBuy -> Buy$32.00 -> $18.00HighView Rating Details
9/16/2016Royal Bank of CanadaReiterated RatingOutperform$25.00N/AView Rating Details
9/6/2016LaidlawInitiated CoverageBuy$20.00N/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Gemphire Therapeutics (NASDAQ:GEMP) Earnings History and Estimates Chart

Earnings by Quarter for Gemphire Therapeutics (NASDAQ:GEMP)

Gemphire Therapeutics (NASDAQ GEMP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/21/2018        
11/13/2017Q3 2017($0.68)($0.82)ViewN/AView Earnings Details
8/14/2017Q2 2017($0.71)($0.99)ViewN/AView Earnings Details
5/9/2017Q1 2017($0.61)($0.79)ViewN/AView Earnings Details
3/15/201712/31/2016($0.54)($0.78)ViewN/AView Earnings Details
11/2/2016Q316($0.45)($0.56)ViewN/AView Earnings Details
9/14/2016Q2 2016($0.23)($0.42)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Gemphire Therapeutics (NASDAQ:GEMP) Earnings Estimates

Current Year EPS Consensus Estimate: $-3.31 EPS
Next Year EPS Consensus Estimate: $-2.79 EPS

Dividends

Dividend History for Gemphire Therapeutics (NASDAQ:GEMP)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Gemphire Therapeutics (NASDAQ GEMP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 34.00%
Institutional Ownership Percentage: 21.22%
Insider Trades by Quarter for Gemphire Therapeutics (NASDAQ:GEMP)
Insider Trades by Quarter for Gemphire Therapeutics (NASDAQ:GEMP)

Gemphire Therapeutics (NASDAQ GEMP) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/8/2018Steven R Ph.D. GullansInsiderBuy71,429$7.00$500,003.00View SEC Filing  
3/10/2017Andy SassineDirectorBuy21,119$9.47$199,996.93136,264View SEC Filing  
8/10/2016David LowenschussInsiderBuy11,120$10.00$111,200.00806,247View SEC Filing  
8/10/2016Jeffrey S MathiesenCFOBuy4,000$10.00$40,000.003,927View SEC Filing  
8/10/2016Mina SoochCEOBuy52,500$10.00$525,000.00693,732View SEC Filing  
8/10/2016Steven R Ph.D. GullansDirectorBuy500,000$10.00$5,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Gemphire Therapeutics (NASDAQ GEMP) News Headlines

Source:
DateHeadline
Gemphire Therapeutics Inc (GEMP) Receives Average Recommendation of "Buy" from BrokeragesGemphire Therapeutics Inc (GEMP) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - February 21 at 12:02 PM
Gemphire to Host Expert Panel Call to Discuss Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) and NASHGemphire to Host Expert Panel Call to Discuss Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) and NASH
feeds.benzinga.com - February 21 at 7:09 AM
Gemphire Therapeutics (GEMP) Rating Increased to Buy at Zacks Investment ResearchGemphire Therapeutics (GEMP) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - February 15 at 11:22 PM
Jefferies Group Comments on Gemphire Therapeutics Incs FY2018 Earnings (GEMP)Jefferies Group Comments on Gemphire Therapeutics Inc's FY2018 Earnings (GEMP)
www.americanbankingnews.com - February 15 at 11:40 AM
Gemphire Therapeutics Inc (GEMP) Interim President & CEO Steven R. Ph.d. ...Gemphire Therapeutics Inc (GEMP) Interim President & CEO Steven R. Ph.d. ...
finance.yahoo.com - February 13 at 9:22 AM
Insider Buying: Gemphire Therapeutics Inc (GEMP) Insider Purchases 71,429 Shares of StockInsider Buying: Gemphire Therapeutics Inc (GEMP) Insider Purchases 71,429 Shares of Stock
www.americanbankingnews.com - February 12 at 6:30 PM
Gemphire Therapeutics (GEMP) Prices 3.14M Common Stock Offering at $7/ShareGemphire Therapeutics (GEMP) Prices 3.14M Common Stock Offering at $7/Share
www.streetinsider.com - February 9 at 3:50 PM
ValuEngine Lowers Gemphire Therapeutics (GEMP) to Strong SellValuEngine Lowers Gemphire Therapeutics (GEMP) to Strong Sell
www.americanbankingnews.com - February 8 at 10:34 PM
Gemphire Announces Pricing of $22 Million Public Offering of Common StockGemphire Announces Pricing of $22 Million Public Offering of Common Stock
finance.yahoo.com - February 8 at 3:39 PM
BRIEF-Gemphire Announces Proposed Public Offering Of Common StockBRIEF-Gemphire Announces Proposed Public Offering Of Common Stock
www.reuters.com - February 8 at 8:08 AM
Gemphire Announces Proposed Public Offering of Common StockGemphire Announces Proposed Public Offering of Common Stock
finance.yahoo.com - February 8 at 8:08 AM
Head-To-Head Analysis: Gemphire Therapeutics (GEMP) vs. TESARO (TSRO)Head-To-Head Analysis: Gemphire Therapeutics (GEMP) vs. TESARO (TSRO)
www.americanbankingnews.com - February 7 at 9:52 AM
BRIEF-Gemphire Announces Initiation Of Phase 2A Clinical Trial Of Pediatric NAFLDBRIEF-Gemphire Announces Initiation Of Phase 2A Clinical Trial Of Pediatric NAFLD
www.reuters.com - February 2 at 3:44 PM
Gemphire Therapeutics (GEMP) Receives Buy Rating from HC WainwrightGemphire Therapeutics (GEMP) Receives Buy Rating from HC Wainwright
www.americanbankingnews.com - February 1 at 1:52 PM
Gemphire Announces Initiation of Phase 2a Clinical Trial of Gemcabene in Pediatric Non-Alcoholic Fatty Liver Disease (NAFLD)Gemphire Announces Initiation of Phase 2a Clinical Trial of Gemcabene in Pediatric Non-Alcoholic Fatty Liver Disease (NAFLD)
finance.yahoo.com - February 1 at 9:10 AM
Gemphire Therapeutics (GEMP) & Affimed (AFMD) Critical ReviewGemphire Therapeutics (GEMP) & Affimed (AFMD) Critical Review
www.americanbankingnews.com - January 30 at 1:20 PM
Gemphire Therapeutics Inc (GEMP) Receives Consensus Recommendation of "Buy" from BrokeragesGemphire Therapeutics Inc (GEMP) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - January 27 at 11:56 AM
Gemphire Therapeutics (GEMP) Price Target Raised to $28.00Gemphire Therapeutics (GEMP) Price Target Raised to $28.00
www.americanbankingnews.com - January 26 at 11:48 PM
BRIEF-Gemphire Completes Patient Enrollment In Indigo-1 TrialBRIEF-Gemphire Completes Patient Enrollment In Indigo-1 Trial
www.reuters.com - January 17 at 5:05 PM
Gemphire Completes Patient Enrollment in INDIGO-1 Trial in Severe Hypertriglyceridemia (SHTG) PatientsGemphire Completes Patient Enrollment in INDIGO-1 Trial in Severe Hypertriglyceridemia (SHTG) Patients
finance.yahoo.com - January 17 at 9:46 AM
Gemphire Therapeutics Inc (GEMP) Receives Average Recommendation of "Buy" from AnalystsGemphire Therapeutics Inc (GEMP) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 2 at 12:44 PM
What Should We Expect From Gemphire Therapeutics Inc’s (NASDAQ:GEMP) Earnings In The Years Ahead?What Should We Expect From Gemphire Therapeutics Inc’s (NASDAQ:GEMP) Earnings In The Years Ahead?
finance.yahoo.com - December 30 at 9:41 AM
Zacks: Brokerages Anticipate Gemphire Therapeutics Inc. (GEMP) to Post -$0.72 Earnings Per ShareZacks: Brokerages Anticipate Gemphire Therapeutics Inc. (GEMP) to Post -$0.72 Earnings Per Share
www.americanbankingnews.com - December 27 at 1:08 AM
Gemphire Therapeutics (GEMP) Buy Rating Reiterated at Roth CapitalGemphire Therapeutics' (GEMP) Buy Rating Reiterated at Roth Capital
www.americanbankingnews.com - December 26 at 2:34 PM
Blog Exposure - Gemphire Therapeutics Launches Clinical Program for Developing Gemcabene as Treatment for NASH/NAFLDBlog Exposure - Gemphire Therapeutics Launches Clinical Program for Developing Gemcabene as Treatment for NASH/NAFLD
finance.yahoo.com - December 26 at 9:14 AM
Comparing Gemphire Therapeutics (GEMP) and AveXis (AVXS)Comparing Gemphire Therapeutics (GEMP) and AveXis (AVXS)
www.americanbankingnews.com - December 25 at 11:06 AM
Gemphire Therapeutics (GEMP) Reports Initiation of its First NASH Proof-of-Concept Clinical Trial and its Differentiated NASH ProgramGemphire Therapeutics (GEMP) Reports Initiation of its First NASH Proof-of-Concept Clinical Trial and its Differentiated NASH Program
www.streetinsider.com - December 22 at 10:01 AM
BRIEF-Gemphire Therapeutics Announces Start Of First Nash Proof-Of-Concept Clinical TrialBRIEF-Gemphire Therapeutics Announces Start Of First Nash Proof-Of-Concept Clinical Trial
www.reuters.com - December 21 at 9:54 AM
Gemphire Therapeutics Inc. (GEMP) Given Consensus Recommendation of "Buy" by AnalystsGemphire Therapeutics Inc. (GEMP) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - December 8 at 11:48 AM
Zacks: Brokerages Anticipate Gemphire Therapeutics Inc. (GEMP) Will Post Earnings of -$0.67 Per ShareZacks: Brokerages Anticipate Gemphire Therapeutics Inc. (GEMP) Will Post Earnings of -$0.67 Per Share
www.americanbankingnews.com - November 21 at 3:14 PM
Gemphire Therapeutics Inc. (GEMP) Rating Lowered to Hold at Zacks Investment ResearchGemphire Therapeutics Inc. (GEMP) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - November 18 at 12:46 AM
FY2017 EPS Estimates for Gemphire Therapeutics Inc. (GEMP) Lowered by AnalystFY2017 EPS Estimates for Gemphire Therapeutics Inc. (GEMP) Lowered by Analyst
www.americanbankingnews.com - November 17 at 8:54 PM
Gemphire Therapeutics Inc. (GEMP) Rating Increased to Buy at Zacks Investment ResearchGemphire Therapeutics Inc. (GEMP) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - November 16 at 10:53 PM
Gemphire Therapeutics Inc. (GEMP) Posts Quarterly  Earnings Results, Misses Expectations By $0.14 EPSGemphire Therapeutics Inc. (GEMP) Posts Quarterly Earnings Results, Misses Expectations By $0.14 EPS
www.americanbankingnews.com - November 15 at 12:56 PM
Gemphire Therapeutics (GEMP) Buy Rating Reiterated at HC WainwrightGemphire Therapeutics' (GEMP) Buy Rating Reiterated at HC Wainwright
www.americanbankingnews.com - November 15 at 12:58 AM
Gemphire Therapeutics Presents Data at American Heart Association (AHA) Scientific Sessions ShowingGemphire Therapeutics Presents Data at American Heart Association (AHA) Scientific Sessions Showing
www.nasdaq.com - November 14 at 5:17 AM
Gemphire Therapeutics Presents Data at American Heart Association (AHA) Scientific Sessions Showing that Gemcabene Significantly Reduces Atherogenic Remnant Lipoprotein and LDL-C as Add-on to Statins in a Cardiometabolic Population and Reports Third Quarter 2017 Financial ResultsGemphire Therapeutics Presents Data at American Heart Association (AHA) Scientific Sessions Showing that Gemcabene Significantly Reduces Atherogenic Remnant Lipoprotein and LDL-C as Add-on to Statins in a Cardiometabolic Population and Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 13 at 7:15 PM
Gemphire Therapeutics Inc. (GEMP) Receives Average Recommendation of "Buy" from AnalystsGemphire Therapeutics Inc. (GEMP) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 13 at 12:34 PM
Analyzing Gemphire Therapeutics (GEMP) and Dimension Therapeutics (DMTX)Analyzing Gemphire Therapeutics (GEMP) and Dimension Therapeutics (DMTX)
www.americanbankingnews.com - November 7 at 7:12 AM
Accomplished BioPharma Executive Mina Sooch Joins BioVie Board of Directors and Purchases Company StockAccomplished BioPharma Executive Mina Sooch Joins BioVie Board of Directors and Purchases Company Stock
finance.yahoo.com - November 2 at 8:23 PM
Gemphire Therapeutics Inc. (GEMP) Stock Rating Lowered by Zacks Investment ResearchGemphire Therapeutics Inc. (GEMP) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - October 25 at 11:08 PM
Gemphire Therapeutics Inc. (GEMP) Upgraded at Zacks Investment ResearchGemphire Therapeutics Inc. (GEMP) Upgraded at Zacks Investment Research
www.americanbankingnews.com - October 23 at 11:20 PM
Gemphire Therapeutics (GEMP) "Buy" Rating Reaffirmed at Canaccord GenuityGemphire Therapeutics' (GEMP) "Buy" Rating Reaffirmed at Canaccord Genuity
www.americanbankingnews.com - October 23 at 9:58 PM
Positive Gemcabene Results in Proof-of-Concept Preclinical NASH Study Presented at The Liver Meeting® 2017Positive Gemcabene Results in Proof-of-Concept Preclinical NASH Study Presented at The Liver Meeting® 2017
finance.yahoo.com - October 23 at 6:46 PM
Gemphire Therapeutics (GEMP) vs. Its Peers Head to Head SurveyGemphire Therapeutics (GEMP) vs. Its Peers Head to Head Survey
www.americanbankingnews.com - October 19 at 4:10 PM
Gemphire Therapeutics Inc. (GEMP) Receives Average Rating of "Buy" from BrokeragesGemphire Therapeutics Inc. (GEMP) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - October 19 at 1:24 PM
Gemphire Therapeutics Inc. (GEMP) Now Covered by Roth CapitalGemphire Therapeutics Inc. (GEMP) Now Covered by Roth Capital
www.americanbankingnews.com - October 19 at 11:44 AM
Gemphire Therapeutics Inc. (GEMP) Rating Increased to Hold at Zacks Investment ResearchGemphire Therapeutics Inc. (GEMP) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - October 16 at 11:20 PM
Gemphire Therapeutics Inc. (GEMP) Given "Buy" Rating at Canaccord GenuityGemphire Therapeutics Inc. (GEMP) Given "Buy" Rating at Canaccord Genuity
www.americanbankingnews.com - October 13 at 5:10 PM
Gemphire to Present New COBALT-1 Clinical Data at the 2017 FH Global Summit - GlobeNewswire (press release)Gemphire to Present New COBALT-1 Clinical Data at the 2017 FH Global Summit - GlobeNewswire (press release)
globenewswire.com - September 27 at 4:09 PM

SEC Filings

Gemphire Therapeutics (NASDAQ:GEMP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Gemphire Therapeutics (NASDAQ:GEMP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Gemphire Therapeutics (NASDAQ GEMP) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.